Sugammadex shortens operation time and improves operation turnover efficacy in VATS.

BACKGROUND: This study compared Sugammadex and Neostigmine as agents for routine neuromuscular blockade reversal in video-assisted thoracoscopic surgery (VATS) to determine the optimal choice that achieves a shorter operation time and improved turnover efficiency while enhancing postoperative outcomes and ensuring patient safety during thoracic surgery.

METHODS: This prospective study, conducted from July 2022 to March 2023, compared the effect of Sugammadex and Neostigmine on operation time and turnover efficiency in VATS, involving 60 participants randomly assigned to either group, with the primary objective of identifying the optimal anesthesia reversal choice for improved outcomes and patient safety during thoracic surgery.

RESULTS: In the study, the Sugammadex group showed a significantly shorter total operation room occupancy time (130±7 vs. 157±7 mins; p=0.009) than the Neostigmine group. Patients in the Neostigmine group had higher mean pulse rates when leaving the operation room (85±3 vs.73±3 beats/min; p=0.002) and 120min later in the Post-anesthesia Care Unit (76±2 vs. 68±2; p=0.016).

CONCLUSION: This study's findings suggest that Sugammadex may enhance total operating room occupancy time, operation turnover efficacy, and respiratory recovery outcomes in VATS, potentially improving patient care and anesthesia management.